尔康制药：前三季度业绩增长 海外项目与技术研发多点推进

Core Viewpoint - The company has shown positive operational performance in the first three quarters of 2025, with significant growth in both revenue and profit, setting a solid foundation for achieving annual business goals [1] Financial Performance - The company achieved operating revenue of 1.006 billion yuan, representing a year-on-year increase of 17.81% [1] - The net profit reached 39.5759 million yuan, marking a turnaround from loss to profit [1] Overseas Expansion - In July 2025, the company approved a $10 million investment through its subsidiary, Erkang Tanzania Co., Ltd., for a comprehensive formulation production project [1] - The project is progressing as planned, with purification engineering and equipment installation underway, expected to complete equipment debugging by Q4 2025, and aims to meet GMP certification conditions [1] - The company is also preparing registration materials for drug approval in compliance with Tanzanian regulatory requirements [1] Technological Development - The company's subsidiary, Hangzhou Longde Intelligent Technology Co., Ltd., is focusing on AI technology applications, particularly in rehabilitation robots and security [1] - The subsidiary has obtained operating qualifications for second-class medical devices, supporting the marketization of related businesses [1] Intellectual Property - The subsidiary has completed the writing of documents for 3 new software copyrights and 2 invention patents, with one patent application receiving initial approval [2] - This enhances the company's intellectual property protection system and accumulates core resources to improve business technical barriers and market competitiveness [2] New Project Initiatives - The company announced plans to invest $8 million in a new injection production project in Nigeria, with an estimated construction period of 18 months [2] - This investment aligns with the company's overall development strategy and aims to expand its business reach and better meet overseas customer demands, potentially becoming a new profit growth point [2]